Guangxi Wuzhou Zhongheng Group (600252.SH): The general medicine series products have a certain level of sales in mainstream domestic chain pharmacies.

Guangxi Wuzhou Zhongheng Group (600252.SH) stated on the investor interaction platform on October 31 that the company is strengthening cooperation with large domestic pharmaceutical commerce enterprises, carrying out distribution and promotion of core products such as Zhonghua Dit da Wan for major domestic chain enterprises and terminal pharmacies, and generic drug series products have certain sales in mainstream chain pharmacies in China.

Gelonghui FinanceOct 31 18:11

Guangxi Wuzhou Zhongheng Group Co., Ltd. 2024 Third Quarter Report

SZSIOct 30 00:00 · Announcements

Express News | Guangxi Wuzhou Zhongheng Group: A holding subsidiary has obtained the registration certificate for the Nimodipine Injection pharmaceutical.

BreakingsOct 29 18:27

Express News | Guangxi Wuzhou Zhongheng Group: Holding subsidiary Chongqing Lummy Pharmaceutical obtains the registration certificate for the Nimodipine Injection pharmaceutical.

BreakingsOct 29 18:25

Guangxi Wuzhou Zhongheng Group (600252.SH): The holding subsidiary has obtained a pharmaceutical supplementary application approval letter.

On October 7th, Guangxi Wuzhou Zhongheng Group (600252.SH) announced that its holding subsidiary Chongqing Lummy Pharmaceutical Co., Ltd. (referred to as "Lummy Pharmaceutical") recently received the National Medical Products Administration's approved cephalosporin cefoperazone dry suspension (specification: 50mg) "Drug Supplementary Application Approval Notice".

Gelonghui FinanceOct 7 16:07

Guangxi Wuzhou Zhongheng Group (600252.SH): Intends to transfer part of its subscribed capital contribution shares of Guohai Zhongheng Fund.

Gelonghui September 25th | Guangxi Wuzhou Zhongheng Group (600252.SH) announced that, based on the current business development situation of the company, the company plans to transfer the 90 million yuan of unpaid subscribed shares and related rights and obligations of Guohai Zhongheng Fund held by the company to the company's related party, Guohai Innovation Capital. Guohai Zhongheng Fund entrusts Shenzhen China Enterprise Hua Land Real Estate Assets Evaluation Co., Ltd. to assess the value of all partners' equity of the fund as of June 30, 2024. The assessed value of the paid-in equity of the fund is 101.5555 million yuan, and the assessed value of the unpaid equity is 0 yuan. This transfer involves the unpaid

Gelonghui FinanceSep 25 17:58